• Elicera Therapeutics named Johan Liwing as chief executive officer, replacing Jamal El-Mosleh.
• Liwing most recently led Lipigon Pharmaceuticals as CEO, reshaping strategy, supporting clinical development, raising capital, driving business development.
• He previously ran XNK Therapeutics, scaling headcount to 24, advancing a lead program to Phase 2, building a GMP-certified cell-therapy facility.
• Earlier, he held Nordic and global roles at Janssen in hematology, market access, strategic partnerships.
• Liwing will buy 355,000 warrants exercisable in three years, priced at 50% above the 20-day volume-weighted average price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 20260817:BIT:8663:0) on August 18, 2026, and is solely responsible for the information contained therein.